NOVO NORDISK A/S-B (NOV.DE) Stock Price & Overview

FRA:NOV • DK0062498333

34.213 EUR
+0.91 (+2.73%)
Last: Mar 9, 2026, 05:16 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

The current stock price of NOV.DE is 34.213 EUR. Today NOV.DE is up by 2.73%. In the past month the price decreased by -15.78%. In the past year, price decreased by -58.47%.

NOV.DE Key Statistics

52-Week Range30.8 - 81.1
Current NOV.DE stock price positioned within its 52-week range.
1-Month Range30.8 - 43.1
Current NOV.DE stock price positioned within its 1-month range.
Market Cap
152.136B
P/E
11.11
Fwd P/E
11.56
EPS (TTM)
3.08
Dividend Yield
4.71%

NOV.DE Stock Performance

Today
+2.73%
1 Week
+4.08%
1 Month
-15.78%
3 Months
-19.43%
Longer-term
6 Months -29.20%
1 Year -58.47%
2 Years -72.24%
3 Years N/A
5 Years N/A
10 Years N/A

NOV.DE Stock Chart

NOVO NORDISK A/S-B / NOV Daily stock chart

NOV.DE Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to NOV.DE. When comparing the yearly performance of all stocks, NOV.DE is a bad performer in the overall market: 95.84% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
NOV.DE Full Technical Analysis Report

NOV.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to NOV.DE. NOV.DE scores excellent on profitability, but there are concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
NOV.DE Full Fundamental Analysis Report

NOV.DE Earnings

On February 3, 2026 NOV.DE reported an EPS of 6.04 and a revenue of 79.14B. The company beat EPS expectations (1.39% surprise) and beat revenue expectations (1.07% surprise).

Next Earnings DateMay 6, 2026
Last Earnings DateFeb 3, 2026
PeriodQ4 / 2025
EPS ReportedDKK6.04
Revenue Reported79.144B
EPS Surprise 1.39%
Revenue Surprise 1.07%
NOV.DE Earnings History

NOV.DE Forecast & Estimates

34 analysts have analysed NOV.DE and the average price target is 49.38 EUR. This implies a price increase of 44.34% is expected in the next year compared to the current price of 34.213.

For the next year, analysts expect an EPS growth of -3.96% and a revenue growth -4.65% for NOV.DE


Analysts
Analysts69.41
Price Target49.38 (44.33%)
EPS Next Y-3.96%
Revenue Next Year-4.65%
NOV.DE Forecast & Estimates

NOV.DE Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

NOV.DE Financial Highlights

Over the last trailing twelve months NOV.DE reported a non-GAAP Earnings per Share(EPS) of 3.08. The EPS increased by 1.77% compared to the year before.


Income Statements
Revenue(TTM)309.06B
Net Income(TTM)102.43B
Industry RankSector Rank
PM (TTM) 33.14%
ROA 18.87%
ROE 52.79%
Debt/Equity 0.61
Chartmill High Growth Momentum
EPS Q2Q%-4.73%
Sales Q2Q%-7.63%
EPS 1Y (TTM)1.77%
Revenue 1Y (TTM)6.43%
NOV.DE financials

NOV.DE Ownership

Ownership
Inst Owners32.22%
Shares4.45B
Float4.18B
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
NOV.DE Ownership

NOV.DE Competitors/Peers

The largest stocks on the EU markets in the "Pharmaceuticals" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
SNW SANOFI9.01184.528B
SAN SANOFI8.96184.503B
1SAN SANOFI8.99184.165B
UCB UCB SA24.8148.822B
UNC UCB SA24.3748.764B
MRK MERCK KGAA13.0347.891B
1MRK MERCK KGAA12.8147.869B
1BAYN BAYER AG-REG7.9936.728B
BAYN BAYER AG-REG835.75B
IPN IPSEN12.6213.485B
REC RECORDATI INDUSTRIA CHIMICA16.379.8B
TUB FINANCIERE DE TUBIZE N/A9.614B
VIRP VIRBAC SA15.912.907B

Related stock screener links

View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges

About NOV.DE

Company Profile

NOV logo image Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Company Info

NOVO NORDISK A/S-B

Novo Alle 1

Bagsvaerd DK

Employees: 68794

NOV Company Website

NOV Investor Relations

Phone: 4544448888

NOVO NORDISK A/S-B / NOV.DE FAQ

What does NOV do?

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.


Can you provide the latest stock price for NOVO NORDISK A/S-B?

The current stock price of NOV.DE is 34.213 EUR. The price increased by 2.73% in the last trading session.


Does NOV stock pay dividends?

NOVO NORDISK A/S-B (NOV.DE) has a dividend yield of 4.71%. The yearly dividend amount is currently 1.56.


How is the ChartMill rating for NOVO NORDISK A/S-B?

NOV.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Would investing in NOVO NORDISK A/S-B be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NOV.DE.


What is the ownership structure of NOVO NORDISK A/S-B (NOV.DE)?

You can find the ownership structure of NOVO NORDISK A/S-B (NOV.DE) on the Ownership tab.